



## SmartPA Criteria Proposal

Drug/Drug Class:	Corticosteroids, Topical PDL Edit		
First Implementation Date:	June 21, 2012		
Revised Date:	December 8, 2022		
Prepared For:	MO HealthNet		
Prepared By:	MO HealthNet/Conduent		
Criteria Status:	⊠Existing Criteria □Revision of Existing Criteria □New Criteria		

## **Executive Summary**

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Topical corticosteroids are used for a variety of inflammatory skin conditions, including atopic dermatitis, seborrheic dermatitis, eczema, and plaque psoriasis.

Pharmacotherapy choices for these conditions typically include emollients and topical corticosteroids. Emollients play an important role in the treatment of atopic dermatitis; however, topical steroids are the standard of care to which other treatments are compared. The selected potency should depend on the severity and location of disease. These agents control symptoms such as swelling, skin cracking, weeping, crusting, and scaling. This PDL class includes all potency classes and does not require additional criteria to gain access to or move from one group to another.

Total program savings for the PDL classes will be regularly reviewed.

## **Program-Specific** Information:

Preferred Agents	Non-Preferred Agents	
<ul> <li>Anusol-HC®</li> <li>Betamethasone Dip Lot</li> <li>Betamethasone Val Crm/Lot/Oint</li> <li>Clobetasol Emollient Crm</li> <li>Clobetasol Prop Crm/Gel/Oint/Soln</li> <li>Fluocinolone Scalp Oil</li> <li>Fluticasone Prop Crm/Oint</li> <li>Hydrocortisone Crm/Lot/Oint Rx</li> <li>Hydrocortisone Crm/Oint OTC</li> <li>Mometasone</li> <li>Procto-Med HC™</li> <li>Proctosol-HC®</li> <li>Proctozone-HC®</li> <li>Triamcinolone Crm/Lot/Oint (excluding gen Trianex®)</li> </ul>	<ul> <li>Ala-Scalp®</li> <li>Alclometasone Dip</li> <li>Amcinonide</li> <li>Apexicon E®</li> <li>Aqua Glycolic® HC Kit</li> <li>Beser™</li> <li>Betamethasone Dip Aug Crm/Gel/Lot/Oint</li> <li>Betamethasone Dip Crm/Oint</li> <li>Betamethasone Val Foam</li> <li>Bryhali®</li> <li>Clobetasol Emollient Foam</li> <li>Clobetasol Prop Foam/Lot/Shampoo/Spray</li> <li>Clocortolone</li> <li>Clodan®</li> <li>Cloderm®</li> <li>Cordran®</li> </ul>	

- Derma-Smoothe/FS®
- Dermatop<sup>®</sup>
- Desonate<sup>®</sup>
- Desonide
- Desoximetasone
- Diflorasone Crm/Oint
- Diprolene<sup>®</sup>
- Elocon<sup>®</sup>
- Fluocinolone Body Oil/Crm/Oint/Soln
- Fluocinonide
- Fluocinonide Emollient
- Flurandrenolide
- Fluticasone Prop Lot
- Halcinonide
- Halobetasol
- Halog<sup>®</sup>
- Hydrocortisone Absorbase Rx
- Hydrocortisone Butyrate
- Hydrocortisone Lot OTC
- Hydrocortisone Valerate
- Hydrocortisone/Aloe
- Impeklo<sup>®</sup>
- Impoyz<sup>®</sup>
- Kenalog<sup>®</sup>
- Lexette<sup>®</sup>
- Locoid<sup>®</sup>
- Locoid Lipocream<sup>®</sup>
- Luxiq<sup>®</sup>
- Micort-HC<sup>®</sup>
- Nolix<sup>®</sup>
- Nucort<sup>™</sup>
- Olux<sup>®</sup>
- Olux-E<sup>®</sup>
- Pandel<sup>®</sup>
- Prednicarbate
- Procto-Pak™
- Sernivo<sup>®</sup>
- Synalar<sup>®</sup>
- Temovate<sup>®</sup>
- Texacort<sup>®</sup>
- Topicort<sup>®</sup>
- Tovet<sup>®</sup>
- Triamcinolone 0.05% Oint (gen Trianex®)
- Triamcinolone Acet Aerosol
- Trianex<sup>®</sup>
- Triderm<sup>™</sup>
- Tridesilon<sup>®</sup>
- Ultravate<sup>®</sup>
- Ultravate<sup>®</sup> X
- Vanos®
- Verdeso<sup>®</sup>

Type of Criteria: ☐ Increased risk of ADE ☐ Appropriate Indications		· · · · · ·	<ul><li>☑ Preferred Drug List</li><li>☐ Clinical Edit</li></ul>		
Data Sources:	☐ Only Administrative Databases		☐ Databases + Prescriber-Supplied		
Setting & Population					
<ul> <li>Drug class for review: Corticosteroids, Topical</li> <li>Age range: All appropriate MO HealthNet participants</li> </ul>					
Approval Criteria					
<ul> <li>Failure to achieve desired therapeutic outcomes with trial on 4 or more preferred agents</li> <li>Documented trial period of preferred agents OR</li> <li>Documented ADE/ADR to preferred agents</li> </ul>					
Denial Criteria					
<ul> <li>Lack of adequate trial on required preferred agents</li> <li>Therapy will be denied if all approval criteria are not met</li> </ul>					
Required Documentation					
Laboratory Resu MedWatch Form		Progress Notes: Other:			
Disposition of Edit					
Denial: Exception Code "0160" (Preferred Drug List) Rule Type: PDL					
Default Approval Period					
1 year					
References					

- Evidence-Based Medicine and Fiscal Analysis: "Topical Corticosteroids Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; January 2022.
- Evidence-Based Medicine Analysis: "Topical Corticosteroids", UMKC-DIC; January 2022.
- USPDI, Micromedex; 2022.
- Facts and Comparisons eAnswers (online); 2022 Clinical Drug Information, LLC.